These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 28894089)

  • 1. Heparan sulfate proteoglycans present PCSK9 to the LDL receptor.
    Gustafsen C; Olsen D; Vilstrup J; Lund S; Reinhardt A; Wellner N; Larsen T; Andersen CBF; Weyer K; Li JP; Seeberger PH; Thirup S; Madsen P; Glerup S
    Nat Commun; 2017 Sep; 8(1):503. PubMed ID: 28894089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake.
    Galvan AM; Chorba JS
    J Lipid Res; 2019 Jan; 60(1):71-84. PubMed ID: 30463987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects].
    Pedro-Botet J; Badimón L
    Clin Investig Arterioscler; 2016 May; 28 Suppl 2():3-8. PubMed ID: 27888903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypercholesterolemia in Progressive Renal Failure Is Associated with Changes in Hepatic Heparan Sulfate - PCSK9 Interaction.
    Shrestha P; Adepu S; Vivès RR; Masri RE; Klooster A; Kaptein F; Dam W; Bakker SJL; van Goor H; van de Sluis B; van den Born J
    J Am Soc Nephrol; 2021 Jun; 32(6):1371-1388. PubMed ID: 33758009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin Does Not Regulate Circulating Human PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) in a General Population-Brief Report.
    Xia VQ; Ong CM; Zier LS; MacGregor JS; Wu AHB; Chorba JS
    Arterioscler Thromb Vasc Biol; 2023 Feb; 43(2):352-358. PubMed ID: 36475702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove.
    Evison BJ; Palmer JT; Lambert G; Treutlein H; Zeng J; Nativel B; Chemello K; Zhu Q; Wang J; Teng Y; Tang W; Xu Y; Rathi AK; Kumar S; Suchowerska AK; Parmar J; Dixon I; Kelly GE; Bonnar J
    Bioorg Med Chem; 2020 Mar; 28(6):115344. PubMed ID: 32051094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A transient amphipathic helix in the prodomain of PCSK9 facilitates binding to low-density lipoprotein particles.
    Sarkar SK; Foo ACY; Matyas A; Asikhia I; Kosenko T; Goto NK; Vergara-Jaque A; Lagace TA
    J Biol Chem; 2020 Feb; 295(8):2285-2298. PubMed ID: 31949048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain.
    Poirier S; Hamouda HA; Villeneuve L; Demers A; Mayer G
    PLoS One; 2016; 11(6):e0157230. PubMed ID: 27280970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alginate oligosaccharide enhances LDL uptake via regulation of LDLR and PCSK9 expression.
    Yang JH; Bang MA; Jang CH; Jo GH; Jung SK; Ki SH
    J Nutr Biochem; 2015 Nov; 26(11):1393-400. PubMed ID: 26320675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regions of conformational flexibility in the proprotein convertase PCSK9 and design of antagonists for LDL cholesterol lowering.
    Kirchhofer D; Burdick DJ; Skelton NJ; Zhang Y; Ultsch M
    Biochem Soc Trans; 2020 Aug; 48(4):1323-1336. PubMed ID: 32794575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAQR3 modulates blood cholesterol level by facilitating interaction between LDLR and PCSK9.
    Huang M; Zhao Z; Cao Q; You X; Wei S; Zhao J; Bai M; Chen Y
    Metabolism; 2019 May; 94():88-95. PubMed ID: 30831144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin.
    Susan-Resiga D; Girard E; Essalmani R; Roubtsova A; Marcinkiewicz J; Derbali RM; Evagelidis A; Byun JH; Lebeau PF; Austin RC; Seidah NG
    J Biol Chem; 2021 Oct; 297(4):101177. PubMed ID: 34508778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing
    Lebeau PF; Byun JH; Platko K; MacDonald ME; Poon SV; Faiyaz M; Seidah NG; Austin RC
    J Biol Chem; 2019 Jun; 294(23):9037-9047. PubMed ID: 31004037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Progress on the molecular mechanisms of PCSK9-mediated degradation of low density lipoprotein receptor].
    Wu YX; Wang Y
    Yi Chuan; 2020 Oct; 42(10):965-978. PubMed ID: 33229322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 23,24-Dihydrocucurbitacin B promotes lipid clearance by dual transcriptional regulation of LDLR and PCSK9.
    Li HH; Li J; Zhang XJ; Li JM; Xi C; Wang WQ; Lu YL; Xuan LJ
    Acta Pharmacol Sin; 2020 Mar; 41(3):327-335. PubMed ID: 31358898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First Food-Derived Peptide Inhibitor of the Protein-Protein Interaction between Gain-of-Function PCSK9
    Grazioso G; Bollati C; Sgrignani J; Arnoldi A; Lammi C
    J Agric Food Chem; 2018 Oct; 66(40):10552-10557. PubMed ID: 30226051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.
    Tavori H; Giunzioni I; Predazzi IM; Plubell D; Shivinsky A; Miles J; Devay RM; Liang H; Rashid S; Linton MF; Fazio S
    Cardiovasc Res; 2016 May; 110(2):268-78. PubMed ID: 26980204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.
    Seidah NG; Abifadel M; Prost S; Boileau C; Prat A
    Pharmacol Rev; 2017 Jan; 69(1):33-52. PubMed ID: 27920219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endoplasmic Reticulum Stress and Ca2+ Depletion Differentially Modulate the Sterol Regulatory Protein PCSK9 to Control Lipid Metabolism.
    Lebeau P; Al-Hashimi A; Sood S; Lhoták Š; Yu P; Gyulay G; Paré G; Chen SR; Trigatti B; Prat A; Seidah NG; Austin RC
    J Biol Chem; 2017 Jan; 292(4):1510-1523. PubMed ID: 27909053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteinuria converts hepatic heparan sulfate to an effective proprotein convertase subtilisin kexin type 9 enzyme binding partner.
    Shrestha P; Yazdani S; Vivès RR; El Masri R; Dam W; van de Sluis B; van den Born J
    Kidney Int; 2021 Jun; 99(6):1369-1381. PubMed ID: 33609572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.